

30th July, 2026

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Security Cover Certificate as on 30-Jun-26 pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

=====

Pursuant to Regulation 54 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), security cover certificate as on 30-Jun-26 certified by B S R & Co. LLP, statutory auditors of the Company is enclosed herewith.

Kindly take note of the above.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M TRIVEDI
COMPANY SECRETARY

Encl: As above

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – investorservices@torrentpharma.com

Private and confidential

The Board of Directors
Torrent Pharmaceuticals Limited
Avirat,
Thaltej Shilaj Road,
Ahmedabad - 380059

30 July 2026

Independent Auditor's report on Statement of Security Cover Certificate of Torrent Pharmaceuticals Limited pursuant to Regulation 54(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI Circular No. SEBI/HO/DDHS-PoD-I/P/CIR/2025/117, dated 13 August 2025 for listed non-Convertible debt securities as at 30 June 2026.

1. This report is being issued with the terms of original engagement letter to the Board of Directors dated 21 September 2022 and addendum to the original agreement dated 22 July 2024.
2. The Management of Torrent Pharmaceuticals Limited (herein after referred as "the Company") has prepared and compiled the accompanying Statement on calculation of Security Coverage Ratio as at 30 June 2026 (hereinafter referred as the "Annexure"). We have been requested by the management of the Company to examine the book value of the assets in Column C to J of the Annexure as at 30 June 2026 as required as per the Debenture Trust Deed between the Company and IDBI Trusteeship Services Limited ("Debenture Trustee"), dated 12 January 2026 (including any amendments thereto) (herein after referred as "the Debenture Trust Deed"), from the unaudited books of accounts and other relevant records and documents maintained by the Company as at and for the quarter ended 30 June 2026 in compliance with the Regulation 54(3) of the Security and Exchange Board of India (SEBI) Listing Obligations And Disclosure Requirements (LODR) Regulations, 2015 (as amended) read with SEBI Circular No. SEBI/HO/DDHS-PoD-I/P/CIR/2025/117, dated 13 August 2025 (herein after cumulatively referred as "the Regulations"). We have signed the accompanying Annexure for identification purposes only.



Management's Responsibility

3. The preparation of the Annexure is the responsibility of the management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation, and maintenance of internal control relevant to the preparation and presentation of the Annexure and applying an appropriate basis of preparation.
4. The Management of the Company is also responsible for ensuring that the Company complies with the requirements of the SEBI LODR Regulations and for providing all relevant information for maintaining Security Coverage Ratio.

Auditor's Responsibility

5. Pursuant to the requirements of the Regulations, it is our responsibility to provide a limited assurance on whether the book value mentioned in Column C to J of the Annexure that forms part of calculation of Security Coverage Ratio are not in agreement with the unaudited books of account, other relevant records and documents maintained by the Company as at and for the quarter ended 30 June 2026.
6. A limited assurance engagement includes performing procedures to obtain sufficient appropriate evidence that vary in nature and timing from a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.
7. The Market Value mentioned in the Annexure has been incorporated by the management of the Company based on valuation carried out by independent valuer vide report dated 23 December 2025. We have not performed any independent procedure in this regard. Our procedures are restricted to the details mentioned in Para 5 above.
8. We conducted our examination of the Annexure in accordance with the "Guidance Note on Reports or Certificates for Special Purposes (Revised 2016)" (referred as 'Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information and Other Assurance and Related Services Engagements.

Conclusion

10. Based on our examination of the unaudited books of account and according to the information and explanations provided to us by the management of the Company, nothing has come to our attention that the book value of assets mentioned in Column C to J of the Annexure that forms part of calculation of security coverage ratio are not in agreement with the unaudited books of account, other relevant records and documents maintained by the Company as at and for the quarter ended 30 June 2026.



Restriction on use

11. This report has been issued at the request of the Company, solely for the purpose of onward submission to National Stock Exchange of India Limited (NSE). It should not be used by any other person or for any other purpose. This report relates only to the Annexure specified above and does not extend to any financial information of the Company or other information. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing. We have no responsibility to update this report for events and circumstances occurring after the date of this report.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sadashiv Shetty

Partner

Ahmedabad
30 July 2026

Membership No: 048648
UDIN: 26048648ILJIS145

Amount Rs in Cr



Notes:

- 1) The security cover on identified trademarks Chymoral, Nexpro, Rozucor, Velez is calculated based on its market value in line with the agreed terms of the debentures.
- 2) The Statutory Auditors are only responsible to certify the book value of the assets mentioned in Column C to J above is in agreement with the unaudited books of accounts and other relevant records and documents maintained by the Company as and for the quarter ended Jun 30, 2026.
- 3) Debt securities to which this certificate pertains includes interest accrued but not due amounting to Rs. 376.12 Crores as at and for the quarter ended Jun 30, 2026.
- 4) The Listed NCD INE685A07132, INE685A07157, INE685A07165 and INE685A07173 are secured against certain identified trademarks / brands of the company and the book value of assets created as a charge against the respective NCD's to which this certificate pertains is Nil. The cover on market value is calculated based on market value of identified trademarks / brand. For calculation of such ratios as mentioned above, the Company has considered market value of identified trademarks / brand against total debts having exclusive charge over such assets and ratios calculated have been aggregated to arrive at total cover on market value of identified trademarks / brand. There is no other debt other than as considered in above calculation that shares Exclusive charge with listed Debt securities to which this certificate pertains to.
- 5) The market value of such brand mentioned in the table above is based on valuation carried out by independent valuer vide certificate dated December 23, 2025. The Statutory auditor have not performed any independent verification in this regard.
- 6) ISIN wise details for Listed Non Convertible Debentures as on Jun 30, 2026:

Sr#	ISIN	Outstanding Principal Amount	Interest accrued but not due	Total outstanding including interest
1	INE685A07132	2,000.00	66.54	2,066.54
2	INE685A07157	2,490.00	84.51	2,574.51
3	INE685A07165	3,000.00	103.16	3,103.16
4	INE685A07173	3,500.00	121.92	3,621.92
	Total	10,990.00	376.12	11,366.12

For Torrent Pharmaceuticals Limited

Mr. Sudhir Menon
Executive Director (Finance) & CFO



Signed for identification purpose only

BSR & Co. LLP